SCPS
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q2 | -0.07 | $0 | -$1M |
| 2023 Q1 | -0.08 | $0 | -$759,856 |
| 2022 Q4 | -0.08 | $0 | -$2M |
| 2022 Q3 | -0.09 | $0 | -$851,654 |
| 2022 Q2 | -0.16 | $0 | -$3M |
| 2022 Q1 | -0.22 | $0 | -$4M |
| 2021 Q4 | -0.38 | $0 | -$6M |
| 2021 Q3 | -0.08 | $0 | -$3M |